Currently Viewing:
American Society of Hematology
Currently Reading
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Derek Raghavan Provides Best Practices for Implementing Guidelines

Physician involvement, patient input, and accuracy are the most important aspects of successfully implementing guidelines, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.


Physician involvement, patient input, and accuracy are the most important aspects of successfully implementing guidelines, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

Transcript

What recommendations for implementing guidelines can physicians and administrators do to start the process off right?

The most important thing for getting guidelines implemented successfully is to ensure that the physicians involved in treatment are actually involved in the creation of guidelines. It doesn’t have to mean that every doctor has his say, but you have to have representation from the leaders of the medical profession, whether it’s in hematologic oncology or solid tumor oncology or even cardiology or hypertension. You have to have the leading doctors at the table, you have to have people who are in community practice who know the reality of being in small offices rather than large centers at the table, able to say, “You could do this in a center of excellence, but we simply can’t do it in an isolated center.” So, you have to have engagement of the medical community.

You need to have input from patients, so you know that what you’re designing is both affordable and acceptable to patient populations. And all of this has to be based on the best available data. If there isn’t good information available about how to do things optimally, then you need to define that your guidelines are less precise and give more leeway until the data are there. At the same time, we do need to incentivize the medical profession to understand that limiting variation is important. That many people who believe that individual judgement may overcall the benefits of that judgement; not to imply that experience or judgement are unimportant, but simply to say that, that experience needs to dovetail with the best evidence that’s published and the best studies that are there.

The other very important aspect of moving guidelines out into the community is to ensure that they are accurate; unfortunately, not all published guidelines are based on the best evidence, there are mistakes that are built in. So, there needs to be a mechanism to amend guidelines that have errors in them, and they have to be simply enough to allow implementation out in the clinical world.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up